Using bio-orthogonally catalyzed lethality strategy to generate mitochondria-targeting anti-tumor metallodrugs in vitro and in vivo

Xuling Xue¹,†, Chenggen Qian³,†, Qin Tao¹, Yuanxin Dai³, Mengdi Lv¹, Jingwen Dong³, Zhi Su¹, Yong Qian¹, Jing Zhao²,*, Hong-Ke Liu¹,∗ and Zijian Guo²,∗

ABSTRACT

Synthetic lethality was proposed nearly a century ago by geneticists and recently applied to develop precision anti-cancer therapies. To exploit the synthetic lethality concept in the design of chemical anti-cancer agents, we developed a bio-orthogonally catalyzed lethality (BCL) strategy to generate targeting anti-tumor metallodrugs both in vitro and in vivo. Metallodrug Ru-rhein was generated from two non-toxic species Ru-N₃ and rhein-alkyne via exclusive endogenous copper-catalyzed azide alkyne cycloaddition (CuAAC) reaction without the need of an external copper catalyst. The non-toxic species Ru-arene complex Ru-N₃ and rhein-alkyne were designed to perform this strategy, and the mitochondrial targeting product Ru-rhein was generated in high yield (>83%) and showed high anti-tumor efficacy in vitro. This BCL strategy achieved a remarkable tumor suppression effect on the tumor-bearing mice models. It is interesting that the combination of metal-arene complexes with rhein via CuAAC reaction could transform two non-toxic species into a targeting anti-cancer metallodrug both in vitro and in vivo, while the product Ru-rhein was non-toxic towards normal cells. This is the first example that exclusive endogenous copper was used to generate metal-based anti-cancer drugs for cancer treatment. The anti-cancer mechanism of Ru-rhein was studied and autophagy was induced by increased reactive oxygen species and mitochondrial damage. The generality of this BCL strategy was also studied and it could be extended to other metal complexes such as Os-arene and Ir-arene complexes. Compared with the traditional methods for cancer treatment, this work presented a new approach to generating targeting metallodrugs in vivo via the BCL strategy from non-toxic species in metal-based chemotherapy.

Keywords: metallodrug, cancer therapy, mitochondrial targeting, bio-orthogonally catalyzed lethality, bio-orthogonal reaction

INTRODUCTION

Synthetic lethality, named by Theodore Dobzhansky in 1946, was an interesting genetic phenomenon originally discovered in Drosophila melanogaster: loss of function of one of two genes alone has little effect on Drosophila viability, whereas inactivation of both genes simultaneously leads to Drosophila death [1]. Synthetic lethality was predicted to be used for the development of anti-cancer drugs [2,3], and a series of poly ADP-ribose polymerase (PARP) inhibitors such as Olaparib (2014), Rucaparib (2016) and Niraparib (2017), have received FDA approval for use in clinical cancer therapies, verifying that synthetic lethality has provided interesting information for the development and clinical approval of other therapies [4]. The advantage of the synthetic lethality-based approach is that it adds a degree of cancer targeting. For example, PARP inhibitors can pose specific cytotoxicity only in cancer cells with a breast cancer (BRCA) gene mutation, no cytotoxicity to the normal cells that do not carry the mutation [5]. However, there are a large number of genetic mutations in cancer cells; it is complicated, time-consuming and expensive to simultaneously screen for two specific genes that can combine and cause lethality.

© The Author(s) 2020. Published by Oxford University Press on behalf of China Science Publishing & Media Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Inspired by the synthetic lethality feature of *Drosophila*, a bio-orthogonally catalyzed lethality (BCL) strategy could be a promising way to avoid screening for specific genes and selectively kill cancer cells while minimizing the side effects towards normal cells. Screening two non-toxic chemical entities that only react efficiently in cancer cells but not normal cells to produce toxic products would make it easier to achieve the synthetic lethality. Bio-orthogonal chemistry has now become one of the most powerful tools in drug discovery and chemical biology [6–9]. Bio-orthogonal chemistry can specifically label and probe a wide variety of biomolecules in living cells and animals [10–13], and is used for drug design and synthesis *in situ* [14–17]. It refers to the chemical reactions that can be performed in living cells or tissues without interfering with the biochemical reaction of the organism itself. The copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) is the most common type of bio-orthogonal reaction, most of which use copper as the catalyst [18,19]. The catalyst Cu species plays a key role in the life system and frequently serves as a catalytic cofactor for enzymes that function in antioxidant defense, iron homeostasis, cellular respiration and a variety of biochemical processes [20]. However, the copper concentrations were reported to be significantly elevated in cancerous tissues compared to normal tissues [21,22], which rendered the copper ion as a target for cancer treatment [23,24]. Therefore, taking advantage of the higher Cu levels in tumor cells to generate cancer-specific drugs *in situ* via CuAAC will help achieve targeting treatment towards tumor cells and avoid toxicity to normal cells. To date, the traditional chemotherapy treatments for cancer include at least two steps: synthesis and purification of certain anti-cancer drugs from raw materials through a series of organic syntheses and purification, and then injection or oral administration into the human body for treatment. It will be a revolutionary breakthrough if the targeting anti-cancer drugs could be generated precisely in live cancer cells and animals from the non-toxic materials in the tumor microenvironment.

Metallo drugs such as ruthenium-arene (Ru-arene) complexes have aroused considerable interest as the basis for new anti-cancer agents due to their specificity in cancer cells, high water solubility, clearance properties and low side effects, which represent desirable characteristics for ideal anti-cancer drugs [25–33]. Results show that the potential target of Ru-arene complexes in the cell might be DNA and their anti-cancer mechanism is quite different from that of cisplatin [26,28–31]. The natural product rhein has been used as a laxative and stomach drug, exhibiting low toxicity towards normal cells [34,35] and mainly located in mitochondria, which may be helpful to increase the mitochondria accumulation of metal species and ultimately improve the anti-tumor activity of the metal complex through mitochondrial targeting if used as ligand. Herein, we describe a BCL strategy to generate metallo drugs in cancer cells *in situ* via CuAAC between two non-toxic compounds, Ru-arene complex Ru-N3 and mitochondria-targeting rhein-alkyne (Fig. 1, Scheme S1). The CuAAC reaction mechanism, determination of the BCL product and its yield *in vitro* were studied by electrospray ionization mass spectrometry (ESI-MS) and ICP-MS (inductively coupled plasma-mass spectrometry); the mitochondrial-targeting ability, anti-tumor cytotoxicity and anti-cancer mechanism were studied by state-of-the-art chemical and physical techniques and cell biological assays. The generality of the BCL strategy was evaluated by using other metal complexes such as Os-arene and Ir-arene complexes. The application of BCL *in vivo* was also performed in the xenograft A549 tumor-bearing mouse model.

**RESULTS AND DISCUSSION**

**Design of the BCL agents**

Compound rhein-alkyne was synthesized by modifying rhein with mono-propargylamine through the amidation reaction, and Ru-N3 was obtained by the reaction of dichloro(p-cymene) ruthenium dimer with 2,2′-dipyridyl-N3 (Scheme S1). For the BCL strategy, all the experiments, such as the mitochondrial-targeting ability, anti-tumor cytotoxicity, reaction mechanism and determination, and anti-cancer mechanistic studies of BCL product *in vitro* were carried out by incubation of the 1:1 mixture of rhein-alkyne and Ru-N3 with a range of cancer cell lines or normal cells, respectively, and the application of BCL *in vivo* was performed in the xenograft A549 tumor-bearing mice model by injection of the 1:1 mixture of rhein-alkyne and Ru-N3. All the comparative experiments were repeated by using chemically synthesized product Ru-rhein and the same procedures. The comparison reactions between the 1:1 rhein-alkyne and Ru-N3 in the chemical reactor were performed with or without additional Cu catalysts, respectively. Only the reaction with additional Cu catalysts gave the final product Ru-rhein, which was purified and characterized by 1H nuclear magnetic resonance (NMR) and ESI-MS spectroscopy (Figs S1–S5). Besides, the UV-vis and photoluminescence spectra of rhein-alkyne and Ru-rhein (10 μM) exhibited that both of them showed good absorption and emission properties (λ_{abs} = ~430 nm, λ_{em} = ~600 nm, 700 nm)
Figure 1. (A) By utilizing the high efficiency and selectivity of the bio-orthogonal reaction, the natural product derivative rhein-alkyne and ruthenium precursor Ru-N3 were designed to generate the anti-cancer metallodrug Ru-rhein in situ with copper species as the catalyst. Besides, the higher copper levels in tumor cells might help realize the bio-orthogonal reaction and kill the tumor cells selectively without the need of an external copper catalyst. (B) Bio-orthogonally catalyzed lethality (BCL) between rhein-alkyne and Ru-N3 in tumor cells. Both rhein-alkyne and Ru-N3 exhibited poor or no cytotoxic activities; once they encountered each other inside the cancer cells, the in situ cycloaddition product Ru-rhein via bio-orthogonal reaction exhibited high cytotoxicity against cancer cells, realizing BCL.

Mitochondrial-targeting of the CuAAC product

To verify the possibility of BCL via CuAAC in living cells, the intracellular distribution of rhein-alkyne and Ru-N3 was conducted using confocal microscopy and ICP-MS methods. We have detected the enrichment of Ru-N3 and rhein-alkyne in different organelles after a short time of incubation. After incubation of 10 μM rhein-alkyne for 4 h or 12 h, the blue fluorescence of rhein-alkyne and red fluorescence of Mito-Tracker overlapped well, with a Pearson’s correlation coefficient of 0.89 (Fig. S7) or 0.90 (Fig. 2A). The intracellular amount of Ru was very small after incubation of 10 μM Ru-N3 for 4 h, but after 8 or 12 h incubation Ru-N3 could enter cells in large amounts and ~65% or 66% were enriched in mitochondria (Fig. 2B and Fig. S8). These suggested that both rhein-alkyne and Ru-N3 were mainly accumulated in the mitochondria of the cells after 8 to 12 h incubation. Moreover, the cellular location of the chemically synthesized Ru-rhein in A549 cells also indicated that the cycloaddition product Ru-rhein was enriched in the mitochondria (Fig. S9). All these results could serve as a basis for the in situ azide-alkyne cycloaddition between rhein-alkyne and Ru-N3.

Anti-tumor cytotoxicity of BCL product

We further determined the anti-tumor cytotoxicities of rhein-alkyne, Ru-N3, mixture of rhein-alkyne and Ru-N3 (molar ratio of 1:1) towards a range of cancer cell lines or normal LO2 and HLF cells through the 3-(4,5)-dimethylthiazolium (-z-y1)-3,5-di-phenyxtetrazoliumromide (MTT) assays, with cisplatin as the control group. As shown in Fig. 2C, both rhein-alkyne and Ru-N3 exhibited little or no cytotoxicity towards cancer cells and two normal cell lines, with the IC50 values ranging from ~46.2 to over ~100.0 μM. However, the growth of the cancer cells was significantly inhibited and the IC50 value was 5.6 μM, as toxic as that of cisplatin (3.3 μM), when 1:1 mixture of rhein-alkyne and
Ru-N$_3$ was added to the A549 cell culture (Fig. S10). Furthermore, the 1:1 mixture of rhein-alkyne and Ru-N$_3$ also exhibited high cytotoxicity against A2780 and MCF-7 cells, with the IC$_{50}$ values of 10.5 $\mu$M and 12.1 $\mu$M, respectively. More importantly, the mixture of rhein-alkyne and Ru-N$_3$ exhibited low toxicity against normal LO2 and HLF cells with IC$_{50}$ values of $\sim$53.9 and $\sim$67.3 $\mu$M (Fig. S11), much lower than that of cisplatin, indicating high selectivity towards cancer cells. These results suggested that the BCL strategy was realized and the anti-tumor efficacy was activated when cycloaddition reaction between rhein-alkyne and Ru-N$_3$ occurred in cancer cells in situ.

**Investigation on the BCL product and CuAAC reaction mechanism *in vitro* **

Based on the high anti-tumor activity of 1:1 mixture of rhein-alkyne and Ru-N$_3$ in cancer cell lines, we hypothesized a metallodrug with high efficacy was generated in the cancer cells. Several experiments were carried out to determine the BCL product *in vitro*. After the A549 cells were treated with 1:1 mixture of rhein-alkyne and Ru-N$_3$, Ru-N$_3$ or rhein-alkyne alone, as well as chemically synthesized Ru-rhein, respectively, the main ingredient inside the cancer cells was characterized by using ESI-MS techniques. For comparison, complexes Ru-N$_3$ or rhein-alkyne, and the chemically synthesized Ru-rhein were also characterized by ESI-MS techniques in methanol solution, respectively. As shown in Figs S12 and S13, it is interesting to note that after the non-toxic species Ru-N$_3$ or rhein-alkyne enters into the A549 cells, their composition remains unchanged, for the positive-ion MS peak (m/Z) at 322.33 assigned for rhein-alkyne or the peak at 496.08 for [Ru-N$_3$–PF$_6$]$^+$; those results match well with the samples measured in methanol solutions. Only one positive-ion peak (m/Z) at 817.25 was observed for the chemically synthesized Ru-rhein in methanol solution (Fig. S5), which was assignable to the cycloaddition product [Ru-rhein–PF$_6$]$^+$ (817.15). It is remarkable that the same two positive-ion peaks (m/Z) at 817.25 and 909.17 were observed for the A549 cells treated with the 1:1 mixture of rhein-alkyne and Ru-N$_3$ (Fig. 2A) and for the chemically synthesized Ru-rhein (Fig. 2B), respectively, and that these isotope patterns for peaks at 817.25 were the same as that observed for the chemically synthesized Ru-rhein in methanol solution, indicating the formation of cycloaddition product Ru-rhein when rhein-alkyne and Ru-N$_3$ encountered each other in A549 cells. The ESI-MS peak at 909.17 might be attributed to the signal of its lysine adduct for [Ru-rhein–PF$_6$–Cl–H$^+$–lysine]$^+$, which was calculated m/Z of 909.34. These results confirmed the
successful generation of Ru-rhein \textit{in vitro} via alkyne-azide cycloaddition of rhein-alkyne and Ru-N\textsubscript{3} without additional Cu catalysts in living cancer cells.

It is worth noting that, without a copper catalyst (CuI or CuSO\textsubscript{4}/NaAsc), the alkyne-azide cycloaddition reaction could not react between Ru-N\textsubscript{3} and rhein-alkyne in N,N-dimethylformamide (DMF) solution, even under the severe conditions of a long time and high temperature. However, such azide-alkyne cycloaddition reaction could react easily without a copper catalyst within the intracellular compartment \textit{in situ} and exhibited high reaction yield for Ru-rhein in mild conditions, which might be attributed to the higher levels of endogenous copper in tumor cells. It is reported that the content of copper ions in lung cancer patients is 1.3–2.0 times more than that of non-cancerous patients. Scanni [36] found that the copper concentration of normal patients was \(~143.03 \mu g/dL\), while the copper levels in cancer patients increased to \(~188 \mu g/dL\), about 1.3 times higher. Diez [37] also pointed out that the copper ion level of Stage III cancer patients, being \(~150 \mu g/dL\) and 100 \(\mu g/dL\) was 1.5 times more than that of normal patients. Thus, we further detected the concentrations of copper species in several cancer and normal cell lines. As shown in Fig. S14, the copper concentrations are \(\sim 41.3, 67.9, 55.1, 24.2\) and 21.6 ppb/10\(^7\) cells in A2780, A549, MCF-7, LO2 and HLF cells respectively, proving that the copper concentrations were indeed higher in the cancer cells than in the normal cells. This was consistent with the cytotoxicities of Ru-rhein, again verifying our design that the higher levels of copper species could enhance the selectivity against cancer cells and the higher levels of intracellular copper species resulted in higher cytotoxicity of Ru-rhein (Table S1). Overall, this suggested that the elevated copper levels in cancer cells might be an important copper source for tumor cells to achieve BCL.

Yields of BCL product Ru-rhein \textit{in vitro}

The ICP-MS technique was used for the first time to determine the yields of BCL product Ru-rhein \textit{in vitro}. Two concentrations (5 and 10 \(\mu M\)) of Ru-N\textsubscript{3} or 1 : 1 mixture of Ru-N\textsubscript{3} and rhein-alkyne were incubated with A549 cells for 24 h and monitored by ICP-MS techniques. As shown in Fig. 3C, the Ru content in the mitochondria of 5 \(\mu M\) Ru-N\textsubscript{3}-loaded A549 cells was determined to be \(~18.7 ng/\mu g\) protein, accounting for 62.8\% of the total Ru content. When the A549 cells were treated with 5 \(\mu M\) 1 : 1 mixture of Ru-N\textsubscript{3} and rhein-alkyne, the Ru content in the mitochondria reached \(~19.3 ng/\mu g\) protein, accounting for 77.5\% of the total quantity, implying that introduction of rhein into the metallodrug could improve the mitochondrial enrichment of Ru species. The yield of Ru-rhein \textit{in vitro} was up to \(~83.6\%), which was obtained via dividing the total content of Ru-rhein in whole A549 cells (24.9 ng) by the total content of Ru-N\textsubscript{3} in whole A549 cells (29.8 ng) \(\times 100\%). Similarly, when the A549 cells were incubated with 10 \(\mu M\) Ru-N\textsubscript{3} or 1 : 1 mixture of Ru-N\textsubscript{3} and rhein-alkyne, respectively, the percentage of Ru in the mitochondria increased from 60.6\% to 75.6\%, and the yield of Ru-rhein \textit{in vitro} was \(~88.0\%). These results indicated that the existence of rhein could enhance the targeting mitochondrial of Ru species, and a higher concentration of 1 : 1 mixture of Ru-N\textsubscript{3} and rhein-alkyne help to generate product in higher yield, both contributing to a greatly improved BCL efficiency.

Mechanistic studies of cell death by BCL product Ru-rhein \textit{in vitro}

Several cell biological assays were used to investigate the mechanism of cell death induced by Ru-rhein \textit{in vitro}. Since the Ru-rhein mainly localized in mitochondria, we supposed that cell death might be related to mitochondrial death pathways. Mitochondria are a major source and may act as a point of integration for death signals originating from both the extrinsic and intrinsic pathways [38], such as an elevation of reactive oxygen species (ROS) levels, variations in mitochondrial membrane potential and the generation of autophagy. The impact of Ru-rhein on intracellular ROS level, mitochondrial membrane potential and autophagy-related protein expression was investigated. When the A549 cells were treated with Ru-rhein, the levels of intracellular ROS increased and the mitochondrial membrane potential was disturbed severely in a concentration-dependent manner (Figs S15–S17). The excess ROS caused obvious oxidative stress and mitochondria dysfunction in A549 cells exposed to Ru-rhein, and we explored whether the cytotoxic effect of Ru-rhein was related to the induction of autophagy.

We further examined the autophagy by using confocal laser scanning microscopy, transmission electron microscopy (TEM) and western blot analysis. Monodansylcadaverine (MDC) staining is a specific assay for autolysosomes, which is dependent on a second ubiquitin-like protein-binding system (located on the membrane of the autophagy vesicle, which can be specifically bound to it) [39]. As shown in Fig. 4A, positively dot-like structures were observed both in the peripheral region of the nucleus and selectively aggregated in the autophagy vesicles when A549 cells were treated with Ru-rhein for 12 h, while no blue fluorescence was observed in the cytoplasm in the control group.
Figure 3. ESI-MS results of A549 cells after treatment with 10 μM Ru-rhein without Cu(I) catalysts (A) and 10 μM chemically synthesized Ru-rhein (B) for 12 h. The m/z peak 817.25 is assigned as [Ru-rhein − PF₆]⁺ (calculated 817.29). The m/z peak 909.17 is assigned as [Ru-rhein − Cl − PF₆ − H + lysine]⁺ (calculated 909.34). The similar m/z peaks at 817.25 of (A) and (B) indicated the successful in situ CuAAC between Ru-N₃ and rhein-alkyne in A549 cells without additional Cu(I) catalysts. (C) Cellular uptake of Ru in A549 cells with 5 and 10 μM Ru-N₃ or Ru-rhein incubation determined by ICP-MS (ng/μg protein).
Figure 4. The cell death mechanism after treatment with Ru-rhein. (A) A549 cells were stained with 5 μM monodansylcadaverine (MDC) for 20 min after treatment with Ru-rhein (5 μM) separately for 24 h and then analyzed by fluorescence microscopy. The increased fluorescence indicated the Ru-rhein-induced formation of autophagosomes. λ<sub>ex</sub> = 405 nm, λ<sub>em</sub> = 430–600 nm for MDC. Scale bar: 10 μm. (B) Transmission electron microscopy imaging showed numerous autophagic vacuoles (red arrows) in A549 cells after treatment with 5 μM Ru-rhein for 24 h. (C and D) The autophagy-related protein expression of LC3 induced by 5 μM cisplatin (1), rhein-alkyne (2), Ru-N<sub>3</sub> (3) and Ru-rhein (4), respectively, in A549 cells for 24 h, observed by western blot analysis. HCQ treatment as the positive control induced autophagy. The data represent the mean ± SEM of three different experiments. **P < 0.01, ***P < 0.001. These results indicated that Ru-rhein mainly caused autophagic cell death of A549 cells.

without Ru-rhein incubation, indicating that Ru-rhein induced the formation of autophagosomes. Ru-rhein-induced autophagy was also monitored by TEM (Fig. 4B). Numerous double-membraned cytosolic autophagic vacuoles in A549 cells were observed after treatment with Ru-rhein for 24 h, while such autophagic vacuoles were not found in the control group without drug treatment. These results verified that significant autophagy occurred in A549 cells after treatment with Ru-rhein.

Moreover, microtubule-associated protein light chain 3 (LC3), as a mammalian homolog of yeast Atg8, has been used as a specific marker to detect autophagy; occurrence of autophagy will render LC3 conjugate to phosphatidylethanolamine and target to autophagic membranes [40]. Western blotting experiments were then performed using an anti-LC3 antibody to verify the expression of related autophagy proteins for A549 cells treated with Ru-rhein. After treatment with cisplatin, rhein-alkyne and Ru-N<sub>3</sub> for 24 h, the expression of LC3-II in A549 cells was almost negligible compared to that in the positive control hydroxychloroquine (HCQ) (Fig. 4C). However, an obvious increase in LC3-II protein expression was observed when A549 cells were treated with Ru-rhein, and the ratio of LC3-I to LC3-II expression was 1.3 times higher than that in the control group without drug treatment (Fig. 4D), proving the induction of autophagy by Ru-rhein, which was consistent with the results of fluorescence confocal images of MDC and TEM images. Taken together, this evidence indicates that Ru-rhein mainly caused autophagic cell death of A549 cells through alterations in oxidative stress and mitochondria membrane potential. Similarly, the main mechanism of chemically synthesized
Figure 5. The successful BCL in vivo. Nude mice bearing A549 tumors were intratumorally injected with various samples at a dosage of 8.0 mg/kg body weight once every three days. The samples included Ru-rhein, rhein-alkyne, Ru-N₃ and saline. (A) Changes in tumor volume during 18 days of the indicated treatments. Data are the mean ± SD (n = 6). (B) Changes in mouse weight during 18 days of the indicated treatments. Data are the mean ± SD (n = 6). (C) Photographs of tumors of each group obtained on the 18th day of treatment. 1: Ru-rhein; 2: rhein-alkyne; 3: Ru-N₃; 4: Saline. (D) Detection of cell death in the tumor tissues after treatment with H&E and TUNEL staining assay after treatment with different samples. Scale bars are 100 μm.

Ru-rhein in causing cell death was also autophagy induced by increased reactive oxygen species and mitochondrial damage (Fig. S18). These results also indicated that the BCL strategy enabled the formation of mitochondria-targeted anti-tumor metallodrug Ru-rhein in vitro. In addition, we also investigated the effects of Ru-rhein treatment on cell cycle and apoptosis of A549 cells, which showed Ru-rhein did not cause cell death by blocking the cell cycle and only caused a small amount of increased population of early apoptotic cells (Figs S19 and S20).

Application of BCL in vivo

Since BCL was achieved successfully in cancer cells in vitro, we further investigated whether BCL could be triggered by endogenous Cu in A549 tumor-bearing mice models. The mice were divided randomly into four groups (six mice/group) and intratumorally injected with Ru-rhein (1 : 1 mixture of Ru-N₃ and rhein-alkyne), rhein-alkyne, Ru-N₃ and saline once every three days for 18 days. As shown in Fig. 5A and C, the growth of the tumors was significantly inhibited after the mice were treated with Ru-rhein, while the mice treated with rhein-alkyne, Ru-N₃ or saline showed rapid growth of the tumors. These results suggested that Ru-rhein displayed high anti-cancer efficacy and achieved BCL in vivo, which was consistent with the in vitro results. Besides, the body weight of the mice treated with different samples showed no obvious change during the cancer treatment (Fig. 5B), indicating that Ru-rhein displayed little toxicity to the mice.

The haematoxylin and eosin (H&E) staining and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining assays were further performed to evaluate the efficacy of different treatments (Fig. 5D). The images of H&E-stained tumor tissue exhibited distinct necrosis of tumor cells treated by Ru-rhein, and the images obtained
from the TUNEL staining also showed the highest level of cell death in the tumor tissue of the mice treated with Ru-rhein. The images of H&E-stained tumor tissue and TUNEL staining after treatment of the control groups (rhein-alkyne, Ru-N3, and saline) could not exhibit obvious tumor necrosis. Besides, the chemically synthesized Ru-rhein could also induce a high level of cell death in the tumor tissue and significantly inhibit the growth of the tumor in vivo (Fig. S21). Taken together, these results suggested that Ru-rhein exhibited satisfactory therapeutic effects in vivo, proving the BCL strategy can also be applied in living mice.

**Generality of the BCL strategy**

To probe the general applicability of BCL, Os-arene and Ir-arene complexes were used to form BCL products via azide-alkyne cycloaddition between two non-toxic species of rhein-alkyne and M-N3 (M=Os, Ir) in cancer cells (Scheme S1). The chemically synthesized complexes were characterized by 1H NMR and ESI-MS spectroscopy (Figs S22–S27). The anti-proliferative activities of the 1:1 mixture of rhein-alkyne and M-N3 (M=Os, Ir) against several cell lines were determined (Table S2); both the rhein-alkyne and M-N3 (M=Os, Ir) complexes exhibited poor or no cytotoxicity, while the cycloaddition products M-rhein (M=Os, Ir) displayed high cytotoxicities with the IC50 value decreasing to 13.3 μM. This not only confirmed the successful cycloaddition reaction between rhein-alkyne and M-N3 (M=Os, Ir) species in living cells, but also showed enhanced cytotoxicities towards cancer cells. These results indicated the potential generality of the BCL strategy, and this strategy might be extended to a wider range for developing metallodrugs for cancer chemotherapy.

**CONCLUSIONS**

Inspired by synthetic lethality, we selected two non-toxic components which could generate efficient anti-cancer species only in cancer cells in situ without an external catalyst. Such strategy is named the BCL strategy. Catalytic products M-rhein (M=Ru, Os or Ir) were generated in vitro by adopting an exclusive endogenous CuAAC reaction between M-N3 and mitochondria-targeting rhein-alkyne without an additional copper catalyst. This BCL strategy generated targeting metallodrugs with high anti-tumor efficacy both in vitro and in vivo and could be extended to a wider range for metallodrugs cancer therapy. Moreover, this BCL strategy could produce the remarkable tumor suppression effect on tumor-bearing mice models. The combination of metal-arene complexes with rhein via CuAAC reaction could transform two non-toxic species into targeting anti-cancer metallodrugs M-rhein (M=Ru, Os and Ir), which are non-toxic to normal cells. The autophagy was the main cause for cancer cell death and this was consistent with the fact that Ru-rhein is a mitochondria-targeting anti-tumor metallodrug. The generality of this strategy was also studied by replacing the metal species with non-toxic Os and Ir precursors. This strategy not only avoided complicated pre-synthesis of the metallodrugs but was also expected to overcome the decomposition and inactivation of the pre-synthesized cycloaddition product in vitro and in vivo. Generation of metallodrugs in vivo by the BCL strategy might be a new approach compared with the traditional treatment pattern of anti-cancer metallodrugs, and might provide a new pattern and platform for precise, targeted and efficient anti-cancer chemotherapy, especially for metal-based drugs.

**SUPPLEMENTARY DATA**

Supplementary data are available at NSR online.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (21420102002, 21771109, 21731004, 21807060, 22077066 and 23025701) and the China Postdoctoral Science Foundation (2019M651874).

**AUTHOR CONTRIBUTIONS**

J.Z., H.L. and Z.G. proposed and supervised the project. X.X., C.Q., J.Z., H.L. and Z.G. conceived and designed the experiment. J.Z., H.L. and Z.G. participated in analyzing the experimental results. Q.T., M.L. and J.D. carried out biological experiments, including the cell and mice experiments. X.X., Q.T. and M.L. carried out the synthesis and most of the structural characterizations. X.X., C.Q., Q.T., Y.D., M.L. and J.D. carried out biological experiments, including the cell and mice experiments. X.X., C.Q., Z.S., Y.Q., J.Z., H.L. and Z.G. co-wrote the manuscript. All authors discussed the results and participated in analyzing the experimental results.

Conflict of interest statement. None declared.

**REFERENCES**

1. Dobzhansky T. Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 1946; 31: 269–90.
2. Hartwell LH, Szankasi P and Roberts CJ et al. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997; 278: 1064–8.
3. Nijman SMB and Friend SH. Potential of the synthetic lethality principle. Science 2013; 342: 809–11.
4. Lord CJ and Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science 2017; 355: 1152–8.
5. Bryant HE, Schultz N and Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 2005; **434**: 913–7.

6. Li J and Chen RP. Development and application of bond cleavage reactions in bioorthogonal chemistry. *Nat Chem Biol* 2016; **12**: 129–37.

7. Prescher JA and Bertozi CR. Chemistry in living systems. *Nat Chem Biol* 2005; **1**: 13–21.

8. Wang J, Liu Y and Liu Y et al. Time-resolved protein activation by proximal decaging in living systems. *Nature* 2019; **569**: 509–13.

9. Fan X, Li J and Chen RP. Bioorthogonal chemistry in living animals. *Nat Sci Rev* 2018; **5**: 137–46.

10. Ngo JT, Adams SR and Deerinck TJ et al. Click-EM for imaging metabolically tagged nonprotein biomolecules. *Nat Chem Biol* 2016; **12**: 459–68.

11. Yang AC, Bois HD and Olsson N et al. Multiple click-deceptive tRNA synthetases expand mammalian cell-specific proteomics. *J Am Chem Soc* 2018; **140**: 7046–51.

12. Shieh P, Dian VT and Beehm BJ et al. CalFluors: a universal motif for fluorogenic azide probes across the visible spectrum. *J Am Chem Soc* 2019; **141**: 7145–51.

13. Wang T, Hong T and Huang Y et al. Fluorescent derivatives as bifunctional molecules for the simultaneous inhibiting and labeling of FTO protein. *J Am Chem Soc* 2015; **137**: 13736–9.

14. Ji X, Pan Z and Yu B et al. Click and release: bioorthogonal approaches to ‘on-demand’ activation of prodrugs. *Chem Soc Rev* 2019; **48**: 1077–94.

15. Qu X, Wang F and Zhang Y et al. A biocompatible heterogeneous MOF-Cu catalyst for in vivo drug synthesis in targeted subcellular organelles. *Angew Chem Int Ed* 2019; **58**: 6987–92.

16. Yao Q, Lin F and Fan X et al. Synergistic enzymatic and bioorthogonal reactions for selective prodrug activation in living systems. *Nat Commun* 2018; **9**: 5032.

17. Du Z, Yu D and Du X et al. Self-triggered click reaction in an Alzheimer’s disease model: in situ bifunctional drug synthesis catalyzed by neurotoxic copper accumulated in amyloid-β plaques. *Chem Sci* 2019; **10**: 10343–50.

18. Wang C, Ikhlef D and Kahal S et al. Metal-catalyzed azide-alkyne ‘click’ reactions: mechanistic overview and recent trends. *Coord Chem Rev* 2016; **316**: 1–20.

19. Hein JE and Fokin VV. Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(I) acetylides. *Chem Soc Rev* 2010; **39**: 1302–15.

20. Lee J, Prhapska JR and Thiele DJ. Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. *Proc Natl Acad Sci USA* 2001; **98**: 6842–7.

21. Wang J, Luo C and Shan C et al. Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. *Nat Chem* 2015; **7**: 968–79.

22. Margalioth EJ, Schenker JG and Chevion M. Copper and zinc levels in normal and malignant tissues. *Cancer* 1983; **5**: 868–72.

23. Gupte A and Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. *Cancer Treat Rev* 2009; **35**: 32–46.

24. Thirumurugan P, Matosia D and Jozwiak K. Click chemistry for drug development and diverse chemical-biology applications. *Chem Rev* 2013; **113**: 4905–79.

25. Brujinincx PCA and Sadler PJ. New trends for metal complexes with anticancer activity. *Curr Opin Chem Biol* 2008; **12**: 197–206.

26. Liu H and Sadler PJ. Metal complexes as DNA intercalators. *Acc Chem Res* 2011; **44**: 349–59.

27. Barry NPE and Sadler PJ. Dicarba-closo-dodecarborane-containing half-sandwich complexes of ruthenium, osmium, rhodium and iridium: biological relevance and synthetic strategies. *Chem Soc Rev* 2012; **41**: 3264–79.

28. Liu H, Parkinson JA and Bella J et al. Penetrative DNA intercalation and G-base selectivity of an organometallic tetrahydroanthracene Ru-II anticancer complex. *Chem Soc Rev* 2010; **1**: 258–70.

29. Li H, Berners-Price SJ and Wang F et al. Diversity in guanine-selective DNA binding modes for an organometallic ruthenium arene complex. *Angew Chem Int Ed* 2006; **45**: 8153–6.

30. Liu H, Wang F and Parkinson JA et al. Ruthenation of duplex and single-stranded d (CGGCCG) by organometallic anticancer complexes. *Chem A Eur J* 2006; **12**: 6151–65.

31. Coverdale JPC, Romero-Canelón I and Sanchez-Can C et al. Asymmetric transfer hydrogenation by synthetic catalysts in cancer cells. *Nat Chem* 2018; **10**: 347–54.

32. Wu Q, Liu L and Li S et al. Rigid dinuclear ruthenium-arene complexes showing strong DNA interactions. *J Inorg Biochem* 2018; **189**: 30–9.

33. Li J, Zhang P and Xu Y et al. A novel strategy to construct Janus metallamacrocycles with both a Ru-arene face and an imidazolium face. *Dalton Trans* 2017; **46**: 16205–15.

34. Chen B, Ye F and Yu L et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. *J Am Chem Soc* 2012; **134**: 17963–71.

35. Li Q, Huang Y and Liu X et al. Rhein inhibits AlkB repair enzymes and sensitizes cells to methylated DNA damage. *J Biol Chem* 2016; **291**: 11083–93.

36. Scanni A, Liciardello L and Trovato M et al. Serum copper and ceruloplasmin levels in patients with neoplasias localized in the stomach, large intestine or lung. *Tumori* 1979; **63**: 175–80.

37. Diez M, Arroyo M and Cerdán FJ et al. Serum and tissue trace metal levels in lung cancer. *Oncology* 1989; **46**: 230–4.

38. Weinberg SE and Chandel NS. Targeting mitochondria metabolism for cancer therapy. *Nat Chem Biol* 2015; **11**: 9–15.

39. Klionsky DJ, Abdelmohsen K and Abe A et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 2016; **12**: 1–222.

40. Klionsky DJ, Cuervo AM and Seglin PO. Methods for monitoring autophagy from yeast to human. *Autophagy* 2007; **3**: 181–206.